Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2005

View Archived Issues

Fuji Photo Film patents contrast agents

Recent patents describe new drugs for gastrointestinal disorders

Low concentrations of SPC-2996 induce potent anticancer effects in preclinical tests

Ranirestat improves nerve conduction velocity in DSP patients

Antitumor efficacy of temsirolimus demonstrated in relapsed mantle cell lymphoma

Apo2L/TRAIL restrains breast cancer-induced bone damage in mice

A novel IL-6R binding peptide inhibits angiogenesis and tumor growth

Pharmos initiates clinical program for NanoEmulsion technology

Completion of phase III trial of Virulizin for pancreatic cancer

Structural GenomiX and CFFT form cystic fibrosis drug discovery alliance

Vernalis to acquire Ionix

Cryptome and NTRI to collaborate in neuroinflammation

Lilly licenses oral DPP-IV inhibitor from Taisho

Astellas ends Aczone agreement for North America

Emisphere receives first milestone in Roche collaboration

TH-9507 begins phase III trial for HIV-associated lipodystrophy

Sumitomo and Merck & Co sign agreement for antipsychotic SM-13496

Novel inhibitor of 17beta-HSD3 identified

LAB begins phase II study for GHRH analogue

Lung cancer chemoprevention study of celecoxib is reactivated

Pancreatic B-cell-selective potassium channel opener reported

Tipifarnib investigated for AML in elderly patients

SGN-00101 studied for prevention of cervical cancer

Update on the antidiabetic effects of sitagliptin

Promising results reported for the CG-8123 anticancer vaccine in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...